Sugi Predict

Sugi Predict / Compounds / SCHEMBL123941

SCHEMBL123941

SCHEMBL123941

CC(=O)OC(=O)c1cccc(C(=O)OC(C)=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CYP4F2 P78329 1/20 0.42
▸ CYP4A11 Q02928 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SLC7A5 Q01650 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ ESR2 Q92731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9247544 0.92 GAA (0.50) TDP1MAPTL3MBTL1MEN1KMT2A
SCHEMBL27264246 0.92 TSHR (0.55) MAPTLOXL2MEN1KMT2ACYP4F2
SCHEMBL2415700 0.88 PARP1 (0.55) TDP1MAPTMEN1KMT2APOLB
SCHEMBL28394006 0.86 PARP1 (0.53) TDP1MAPTL3MBTL1MEN1KMT2A
SCHEMBL27597152 0.86 PARP1 (0.53) MAPTL3MBTL1TSHRRAB9AALDH1A1
SCHEMBL6934827 0.85 ALDH1A1 (0.47) TDP1MAPTL3MBTL1TSHRPOLB
SCHEMBL5279551 0.85 CES2 (0.65) MEN1KMT2ATSHRCES2CES1
SCHEMBL29287804 0.85 MAPT (0.63) TDP1MAPTLMNAGAA
SCHEMBL28555480 0.84 LMNA (0.62) TDP1MEN1KMT2ATSHRPOLB
SCHEMBL35098 0.84 TSHR (0.60) TDP1MAPTL3MBTL1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3925601-B1 GASTRO-RESISTANT FORMULATION CONTAINING POSACONAZOLE AND A POLYMERIC PRECIPITATION INHIBITOR TIEFENBACHER ALFRED E GMBH & CO KG (DE) 2024-07-17 — — EP claimed
US-20240207264-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF ESSA PHARMA INC. (CA) 2024-06-27 — — US claimed
WO-2024119044-A2 ADRULIPASE COMPOSITIONS First Wave BioPharma, Inc. (US) 2024-06-06 — — WO claimed
EP-4322933-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF ESSA PHARMA INC. (CA) 2024-02-21 — — EP claimed
WO-2024035618-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-02-15 — — WO claimed
US-20240009135-A1 DENSIFIED CO-PRECIPITATED MATERIALS ISOLATED BY THIN FILM EVAPORATION MERCK SHARP & DOHME LLC (US) 2024-01-11 — — US claimed
EP-4084778-B1 AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-11-01 — — EP claimed
US-20230285352-A1 Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2023-09-14 — — US claimed
EP-4214183-A1 PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF Essa Pharma, Inc. (CA) 2023-07-26 — — EP claimed
CN-116437947-A Non-pig formulations and methods thereof 第一浪潮生物制药有限公司 2023-07-14 — — CN claimed
WO-2002011710-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2002-02-14 — — WO claimed
US-20020006443-A1 Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form BEND RESEARCH, INC. 2002-01-17 — — US claimed
US-20010053791-A1 Glycogen phosphorylase inhibitor BEND RESEARCH, INC. 2001-12-20 — — US claimed
US-20010053778-A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors BEND RESEARCH, INC. 2001-12-20 — — US claimed
WO-2001068055-A1 PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER PRODUCTS INC. (US) 2001-09-20 — — WO claimed
WO-2001068092-A2 GLYCOGEN PHOSPHORYLASE INHIBITOR PFIZER PRODUCTS INC. (US) 2001-09-20 — — WO claimed
WO-2001047495-A1 PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS PFIZER PRODUCTS INC. (US) 2001-07-05 — — WO claimed
WO-2001047492-A1 IMPROVED PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS F H FAULDING & CO LIMITED (AU) 2001-07-05 — — WO claimed
EP-1027886-A2 Pharmaceutical solid dispersions Pfizer Products Inc. (US) 2000-08-16 — — EP claimed
EP-1027887-A2 Matrix controlled release device Pfizer Products Inc. (US) 2000-08-16 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207264-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF AR, NR5A1, SHBG TDP1 2606/4885MAPT 2835/4885LOXL2 4004/4885
US-20010053791-A1 Glycogen phosphorylase inhibitor PYGL, PYGM, GYS2 TDP1 467/4885MAPT 712/4885LOXL2 3096/4885
US-20010053778-A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors PYGL, PYGM, GYS2 TDP1 334/4885MAPT 399/4885LOXL2 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.